Living with hemophilia means constantly worrying about bleeds that can be painful and limit what you can do. A recent analysis pooled data from six studies involving 397 males with hemophilia A or B, looking at newer preventive therapies like emicizumab, fitusiran, and concizumab. It found that these therapies likely reduce annual bleeding rates and increase the chance of having zero bleeds compared to on-demand treatment, and they may also improve quality of life scores, helping people feel better physically and overall.
However, it's not all smooth sailing. These newer therapies were linked to more non-serious adverse events, with injection site reactions being common, and some participants developed temporary antibodies to fitusiran and concizumab. The analysis didn't show a clear difference in serious adverse events for those without inhibitors, but the full safety picture isn't complete since discontinuation rates and tolerability weren't reported.
It's important to keep the findings in perspective. The evidence comes from randomized controlled trials, which are strong, but the certainty ranges from moderate to very low depending on the outcome, and the studies didn't assess long-term joint health, clinical joint function, or economic outcomes. Also, one therapy, marstacimab, wasn't evaluated at all. So while these results are promising, they don't tell us everything about how these therapies work over time or in broader populations.